Dimerix Ltd. sealed an exclusive license agreement with Amicus Therapeutics Inc. for commercialization of its phase III kidney disease candidate, DMX-200, in a deal valued at AU$940 million (US$601.22 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback